Literature DB >> 31002780

Circulating PCSK9 concentrations are increased in postmenopausal women with the metabolic syndrome.

Nutjaree Jeenduang1.   

Abstract

BACKGROUND: High PCSK9 concentrations are associated with an increased risk of cardiovascular disease (CVD). We investigated PCSK9 concentrations and their association with metabolic parameters in Thai subjects and to compare PCSK9 concentrations in pre- and postmenopausal women with and without metabolic syndrome (MetS).
METHODS: Anthropometric data, serum lipids, fasting blood glucose (FBG), and PCSK9 concentrations were measured in 436 Thai subjects (152 men, 143 premenopausal, and 141 postmenopausal women).
RESULTS: PCSK9 concentrations were significantly higher in women than in men (p = .002) and increased in subjects with an increasing number of MetS components (p for trend = .011). PCSK9 concentrations were significantly higher in postmenopausal women than in premenopausal women (p < .001), in the MetS group than in the non-MetS group (p = .037), and in postmenopausal women with MetS than in premenopausal women without MetS (p < .001). Serum PCSK9 concentrations were positively correlated with several metabolic parameters, including age, BMI, systolic blood pressure (SBP), total cholesterol, triglyceride, LDL-C, and FBG.
CONCLUSION: PCSK9 concentrations are influenced by age, gender, MetS status, and menopausal status among Thai subjects. These findings suggest that an elevation in PCSK9 concentrations may increase cardiovascular risk in postmenopausal women with MetS.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Menopause; Metabolic parameters; Metabolic syndrome; PCSK9

Mesh:

Substances:

Year:  2019        PMID: 31002780     DOI: 10.1016/j.cca.2019.04.067

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

Review 1.  Proprotein Convertase Subtilisin/Kexin Type 9, Angiopoietin-Like Protein 8, Sortilin, and Cholesteryl Ester Transfer Protein-Friends of Foes for Psoriatic Patients at the Risk of Developing Cardiometabolic Syndrome?

Authors:  Julita Anna Krahel; Anna Baran; Tomasz W Kamiński; Iwona Flisiak
Journal:  Int J Mol Sci       Date:  2020-05-23       Impact factor: 5.923

2.  Methotrexate Decreases the Level of PCSK9-A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data.

Authors:  Julita Anna Krahel; Anna Baran; Tomasz W Kamiński; Magdalena Maciaszek; Iwona Flisiak
Journal:  J Clin Med       Date:  2020-03-26       Impact factor: 4.241

3.  PCSK9 inhibitor and atorvastatin reduce cardiac impairment in ovariectomized prediabetic rats via improved mitochondrial function and Ca2+ regulation.

Authors:  Patchareeya Amput; Siripong Palee; Busarin Arunsak; Wasana Pratchayasakul; Chanisa Thonusin; Sasiwan Kerdphoo; Thidarat Jaiwongkam; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  J Cell Mol Med       Date:  2020-07-06       Impact factor: 5.310

4.  Sex differences in the non-linear association between BMI and LDL cholesterol in middle-aged and older adults: findings from two nationally representative surveys in China.

Authors:  Haibin Li; Jiahui Ma; Deqiang Zheng; Xia Li; Xiuhua Guo; Jing Wang; Pixiong Su
Journal:  Lipids Health Dis       Date:  2021-11-14       Impact factor: 3.876

Review 5.  Sex difference in circulating PCSK9 and its clinical implications.

Authors:  Fang Jia; Si-Fan Fei; De-Bing Tong; Cong Xue; Jian-Jun Li
Journal:  Front Pharmacol       Date:  2022-09-07       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.